NUVB - Nuvation Bio Inc.

QQQ $ 473.14 $ -2.10 (-0.44 %)

DIA $ 417.33 $ 2.44 (0.59 %)

SPY $ 562.48 $ 0.83 (0.15 %)

TLT $ 101.29 $ 0.92 (0.92 %)

GLD $ 238.61 $ -0.02 (-0.01 %)

Previous Close

$ 3.07

Open

$ 3.08

Bid

$ 3.07 x 386

Ask

-- x --

Day's Range

$ 3.01 - $ 3.15

52 Week Range

$ 0.95 - $ 4.16

Volume

1,942,718

Average Volume

Market Cap

765.18M

Beta (5Y Monthly)

$ 1.10

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2024	06-30-2024	10-Q
2	05-14-2024	03-31-2024	10-Q
3	02-29-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	03-15-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-12-2021	06-30-2021	10-Q
14	05-17-2021	03-31-2021	10-Q
15	03-11-2021	12-31-2020	10-K
16	11-16-2020	09-30-2020	10-Q
17	08-14-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Maintains Buy on Nuvat...
09/16/2024 11:05:15

HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and lowers the price target from ...

Reported Saturday, Nuvation Bio Announces ...
09/16/2024 08:51:07

Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)...

Wedbush Reiterates Outperform on Nuvation ...
09/11/2024 13:08:22

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.

why-oracle-shares-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket

Why Oracle Shares Are Trading Higher By Ar...
09/10/2024 10:41:15

RBC Capital Reiterates Outperform on Nuvat...
08/06/2024 12:48:12

RBC Capital analyst Gregory Renza reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.

small-cap-cancer-focused-nuvation-bio-pulls-plug-on-early-stage-program-after-considering-phase-1-solid-tumor-data

Small-Cap Cancer-Focused Nuvation Bio Pull...
08/05/2024 18:27:54

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments ...

Nuvation Bio's Cash, Cash Equivalents, And...
08/05/2024 12:16:54

Nuvation Bio Q2 2024 GAAP EPS $(1.89) May ...
08/05/2024 12:14:42

Nuvation Bio Announces Updates And Upcomin...
07/23/2024 20:11:54

Company to present pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society of Medical Oncolog...

HC Wainwright & Co. Reiterates Buy on Nuva...
07/17/2024 10:34:22

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.

neurobo-pharmaceuticals-and-2-other-penny-stocks-insiders-are-buying

NeuroBo Pharmaceuticals And 2 Other Penny ...
06/26/2024 12:48:53

HC Wainwright & Co. Reiterates Buy on Nuva...
06/03/2024 10:37:09

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.

Reported Saturday, Nuvation Bio Revealed F...
06/03/2024 08:49:39

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of t...

Wedbush Reiterates Outperform on Nuvation ...
05/24/2024 13:52:29

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.

HC Wainwright & Co. Reiterates Buy on Nuva...
05/22/2024 10:33:04

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.

Wedbush Reiterates Outperform on Nuvation ...
05/15/2024 13:42:28

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.

Nuvation Bio Q1 2024 Adj EPS $(0.07) Beats...
05/14/2024 20:31:40

Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by...

Fifth Third Bancorp Reports Upbeat Earning...
04/19/2024 14:40:21

RBC Capital Maintains Outperform on Nuvati...
04/17/2024 14:56:04

RBC Capital analyst Kennen MacKay maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $4 t...

profoundbio-discovers-the-joys-of-having-a-wealthy-owner

ProfoundBio Discovers The Joys Of Having A...
04/08/2024 15:43:57

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...